Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo

Neurology

Volumn 74, Issue 11, 2010, Pages 885-892

  Klein, J C ^a   Eggers, C ^b   Kalbe, E ^b,c   Weisenbach, S ^d   Hohmann, C ^e   Vollmar, S ^e   Baudrexel, S ^a   Diederich, N J ^f   Heiss, W D ^e   Hilker, R ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c FORSCHUNGSZENTRUM JÜLICH   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^f CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

6 FLUORODOPA F 18; ACETYLCHOLINE; CARBIDOPA; DOPAMINE; FLUORODEOXYGLUCOSE F 18; METHYL 4 PIPERIDYL ACETATE C 11; RADIOLIGAND; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE;

ADULT; ARTICLE; ASSOCIATION CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEAFFERENTATION; DIFFUSE LEWY BODY DISEASE; DRUG BINDING; DRUG UPTAKE; ENERGY METABOLISM; FOREBRAIN; FRONTAL CORTEX; HUMAN; IN VIVO STUDY; LIMBIC SYSTEM; MOTOR DYSFUNCTION; NEOCORTEX; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; STATISTICAL PARAMETERS; VOXEL BASED MORPHOMETRY; AGED; BRAIN; BRAIN MAPPING; IMAGE PROCESSING; LEWY BODY; METABOLISM; METHODOLOGY; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; SCINTISCANNING; THREE DIMENSIONAL IMAGING;

ACETYLCHOLINE; AGED; BRAIN; BRAIN MAPPING; DIHYDROXYPHENYLALANINE; DOPAMINE; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; LEWY BODIES; LEWY BODY DISEASE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY;

EID: 77950511411     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181d55f61     Document Type: Article

References (38)

1. Emre M, Aarsland D, Brown R, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007;22:1689-1707. (Pubitemid 47597592)
2. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-1872.
3. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004;17:137-145. (Pubitemid 39128223)
4. Lippa CF, Duda JE, Grossman M, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007;68:812-819.
5. Edison P, Rowe CC, Rinne JO, et al. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11CJPIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-1338.
6. Maetzler W, Reimold M, Liepelt I, et al. [11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39: 1027-1033.
7. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
8. Hilker R, Klein C, Ghaemi M, et al. Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol 2001;49:367-376.
9. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23 suppl 1:S208-S219.
10. Patlak CS, Blasberg RG. Graphical evaluation of blood-to- brain transfer constants from multiple-time uptake data. Generalizations J Cereb Blood Flow Metab 1985;5:584-590.
11. Ashburner J, Friston KJ. Nonlinear spatial normalization using basis functions. Hum Brain Mapp 1999;7:254-266.
12. Herholz K, Weisenbach S, Zundorf G, et al. In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. Neuroimage 2004;21:136-143.
13. Zuendorf G, Herholz K, Lercher M, et al. PET functional parametric images of acetylcholine esterase activity without blood sampling In: Senda M, Kimura Y, Herscovhch P, eds. Brain Imaging Using PET. San Diego, CA: Academic Press; 2002:41-46.
14. Wienhard K, Pawlik G, Herholz K, Wagner R, Heiss WD. Estimation of local cerebral glucose utilization by positron emission tomography of [F-18]2-fluoro-2- deoxy-D-glucose: a critical appraisal of optimization procedures. J Cereb Blood Flow Metab 1985;5:115-125.
15. Friston KJ. Statistical Parametric Mapping: The Analysis of Functional Brain Images, 1st ed. Amsterdam: Elsevier/ Academic Press; 2007.
16. Hu XS, Okamura N, Arai H, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000;55:1575-1577.
17. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005;65:1716-1722.
18. O'Brien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-925.
19. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
20. Woods SP, Troster AL Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003;9:17-24.
21. Kovari E, Gold G, Herrmann FR, et al. Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathol 2003;106:83-88.
22. Bohnen NI, Kaufer DI, Hendrickson R, et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006;253:242-247.
23. Bohnen NI, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.
24. Shimada H, Hirano S, Shinotoh H, et al. Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 2009;73:273-278.
25. Lippa CF, Smith TW, Perry E. Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. J Neural Transm 1999;106:525-535.
26. Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 2005;65:1239-1245.
27. Ballard C, Ziabreva I, Perry R, et al. Differences in neuropathology characteristics across the Lewy body dementia spectrum. Neurology 2006;67:1931-1934.
28. Rodrigo J, Fernandez P, Bentura ML, et al. Distribution of catecholaminergic afferent fibres in the rat globus pallidus and their relations with cholinergic neurons. J Chem Neuroanat 1998;15:1-20.
29. Colloby S, O'Brien J. Functional imaging in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 2004;17:158-163. (Pubitemid 39128225)
30. Gjedde A, Marrett S, Vafaee M. Oxidative and nonoxidative metabolism of excited neurons and astrocytes. J Cereb Blood Flow Metab 2002;22:1-14.
31. Maclnnes N, Iravani MM, Perry E, et al. Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. J Neural Transm 2008;115:869-878.
32. Hurtig HI, Trojanowski JQ, Galvin J, et al. Alphasynuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology 2000;54:1916-1921.
33. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alphasynuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007; 27:1405-1410.
34. Trojanowski JQ, Lee VM. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann NY Acad Sci 2003;991:107-110.
35. Mastaglia FL, Johnsen RD, Byrnes ML, Kakulas BA. Prevalence of amyloidbeta deposition in the cerebral cortex in Parkinson's disease. Mov Disord 2003; 18:81-86.
36. Lashley T, Holton JL, Gray E, et al. Cortical alphasynuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008;115:417-425.
37. Gomperts SN, Rentz DM, Moran E, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71:903-910.
38. Rowe CC, Ng S, Ackermann U, et al. Imaging betaamyloid burden in aging and dementia. Neurology 2007; 68:1718-1725.